

NEEDLE-FREE INJECTION – VACCINE BREAKTHROUGH

Key points:

- **Further Needle-free prototype laboratory trial results**
- **Targeted immune response in 100% of animals injected with Hepatitis B antigen**

Medical technologies group Norwood Abbey Ltd [ASX:NAL] is pleased to advise further progress in the needle-free injection system project being undertaken at the BioInstrumentation Laboratory at Massachusetts Institute of Technology (MIT) under the direction of Prof Ian Hunter.

Norwood advises that researchers at MIT have achieved a very significant breakthrough in respect to the delivery of vaccines with Norwood's needle-free device.

MIT researchers achieved an immune response in a trial to test the suitability and efficacy of its needle-free devices to deliver vaccines.

All animals injected with the vaccine using the Norwood needle-free device showed the anticipated immune response. The Hepatitis B surface antigen was chosen as representative of typical vaccines.

Achievement of an immune response indicates that vaccines can be successfully injected with Norwood's needle-free device.

The original aim of the project was to develop a low cost and silent needle-free injection device to deliver vaccines to a targeted depth.

Norwood believes that the outstanding success of this first trial will be of assistance in attracting prospective partners with respect to the delivery of pharmaceuticals, biologicals and especially vaccines.

For further information visit www.norwoodabbey.com

For further information please contact:

Norwood Abbey Ltd
Lula Lioffi
Corporate Communications Manager
+61-3-9770 0063